What smart money is saying about Ascendis Pharma
1 fund in our archive has pitched Ascendis Pharma — most recently Artisan Partners U.S. Small-Cap Growth Strategy in June 2026.
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Fund activity · 2 positions · 1 move
- HoldsArtisan Partners U.S. Mid‑Cap Growth StrategyJune 2026
“In health care, we saw strong earnings and stock returns from biotech drug companies like Argenx and Ascendis Pharma, as well as from life sciences tools and diagnostics innovators such as Twist Bioscience, Guardant Health and Veracyte.”
Read the letterAscendis Pharma - TrimmedArtisan Partners U.S. Small-Cap Growth StrategyJune 2026
“We reduced the position during the quarter after a competitor with an existing treatment for the same rare hormone disorder as YORVIPATH® filed a lawsuit against Ascendis.”
Read the letterAscendis Pharma
Fund coverage · 1 thesis
- Artisan Partners U.S. Small-Cap Growth StrategyJune 2026
Ascendis Pharma uses its TransCon platform to develop differentiated rare-disease therapies, with strong patient growth supporting long-term conviction.
Read the full thesis
Read every full thesis on Ascendis Pharma
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→